Vinge advises Ampersand Capital Partners, a Boston based private equity firm, in connection with the forming of the Gyros Protein Technologies group. The new group consists of Ampersand’s portfolio company Protein Technologies, Inc., a US based provider of peptide synthesis instrumentation and reagents, and the Swedish Gyros group operating within automated nanoliter-scale immunoassays, who’s majority owner is the Swedish Sixth National Pension Fund.
Vinge’s team consisted of, among others, the partner in charge Christina Kokko and Kristina Ekberg, Oscar Rydén and Maria Schultzberg.
